For the roughly 4,000 to 5,000 Americans diagnosed with mantle cell lymphoma each year, running out of treatment options can happen fast. The cancer is one of the more aggressive forms of non-Hodgkin lymphoma, and patients whose disease returns after chemotherapy and a BTK inhibitor face a shrinking list of next steps. On May 13, 2026, the FDA added a new one: a once-daily pill called Beqalzi (sonrotoclax) that targets the protein keeping their cancer cells alive.
The accelerated approval covers adults with relapsed or refractory mantle cell lymphoma who have already been through at least two prior lines of systemic therapy, including a BTK inhibitor such as ibrutinib or acalabrutinib. The drug was developed by BeOne Medicines (formerly operating under the BeiGene name), which confirmed the approval in a Form 6-K filed with the U.S. Securities and Exchange Commission.
How sonrotoclax attacks the cancer
Mantle cell lymphoma cells have a survival trick: they crank up production of a protein called BCL-2. In healthy tissue, BCL-2 plays a normal role in regulating apoptosis, the process by which damaged or unnecessary cells self-destruct. But when lymphoma cells flood themselves with BCL-2, they essentially lock their own death switch in the “off” position, allowing them to keep dividing even after chemotherapy or targeted drugs have damaged them.
Sonrotoclax is a BCL-2 inhibitor. It binds directly to the BCL-2 protein and blocks its protective effect, restoring the cell’s ability to trigger its own destruction. The concept is not entirely new. Venetoclax (Venclexta), approved years ago for chronic lymphocytic leukemia and certain types of acute myeloid leukemia, works through the same mechanism. But venetoclax does not carry an FDA-approved indication for mantle cell lymphoma, which has left a gap that sonrotoclax now fills for patients in the third-line setting and beyond.
The clinical evidence behind the approval
The FDA based its decision on results from a single-arm, multicenter phase 1/2 study known as BGB-11417-201, registered on ClinicalTrials.gov as NCT05471843. The trial enrolled patients with relapsed or refractory mantle cell lymphoma who had already received a BTK inhibitor. Early results from the trial program were published in a hematology journal under the title “Sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory mantle cell lymphoma previously treated with a BTK inhibitor.”
Because the approval came through the FDA’s accelerated pathway, the key efficacy measure was overall response rate, a surrogate endpoint that captures how many patients saw their tumors shrink meaningfully. The specific response rate and median duration of response have not yet been detailed in the publicly available FDA approval summary. That means oncologists cannot yet make precise head-to-head comparisons with other late-line options, including CAR-T cell therapy (brexucabtagene autoleucel, marketed as Tecartus) or the third-generation BTK inhibitor pirtobrutinib (Jaypirca), both of which also carry approvals for relapsed mantle cell lymphoma.
The approval also appears in the FDA’s running oncology approvals index, confirming the action is recorded in the agency’s public database.
Safety questions that still need answers
BCL-2 inhibitors carry a well-known class risk: tumor lysis syndrome. When large numbers of cancer cells die rapidly, they dump their internal contents, including potassium, phosphorus, and uric acid, into the bloodstream. The resulting metabolic surge can damage the kidneys and heart if not managed carefully. With venetoclax, this risk is mitigated through a gradual dose ramp-up over several weeks, and patients are monitored closely during the early phase of treatment. Whether sonrotoclax requires a similar ramp-up schedule, and whether it triggers tumor lysis syndrome at comparable rates, are details the full prescribing label will need to clarify.
Other class-related side effects, including low blood counts (cytopenias) and increased susceptibility to infections, will also need careful tracking as more patients receive the drug outside the controlled setting of a clinical trial. Detailed adverse-event frequencies from the BGB-11417-201 study have not been broken out in the publicly available regulatory summary reviewed as of late May 2026.
The confirmatory trial requirement
Accelerated approval is not the same as full approval. Under the FDA’s expedited programs framework, BeOne Medicines must complete a confirmatory trial demonstrating that the tumor responses seen in the phase 1/2 study translate into a clear clinical benefit, such as longer overall survival or sustained remission. If that confirmatory study fails, the FDA has the authority to initiate proceedings to pull the drug from the market.
The design, endpoints, and timeline for the confirmatory study have not been publicly disclosed in detail. That uncertainty matters for clinicians trying to counsel patients about how much confidence to place in the drug’s long-term value. It also matters for insurers, who may impose prior authorization requirements or step-therapy rules when coverage decisions rest on early-phase data rather than mature survival outcomes.
What this means for patients facing limited options
Mantle cell lymphoma accounts for roughly 6% of all non-Hodgkin lymphomas in the United States. While some patients respond well to initial chemotherapy and can remain in remission for years, the disease almost always relapses. Each successive line of treatment tends to produce shorter remissions, and by the time patients have exhausted both chemotherapy and a BTK inhibitor, the available choices narrow considerably.
Sonrotoclax does not replace those earlier treatments. It slots in as a new option for patients who have already been through them. For someone whose mantle cell lymphoma has returned after two or more prior therapies, the practical question is whether to pursue sonrotoclax, CAR-T cell therapy, pirtobrutinib (if not already tried), or a clinical trial. Each carries different trade-offs in terms of efficacy, side effects, logistics, and cost.
Pricing for Beqalzi has not been announced. For a patient population that skews older, often with other health conditions and fixed incomes, the out-of-pocket burden of a new oral targeted therapy can be the difference between filling a prescription and not. Until list prices and payer coverage policies are established, access will remain an open question.
What is clear as of late May 2026 is that sonrotoclax represents a biologically rational addition to the mantle cell lymphoma toolkit: a drug built to exploit a known vulnerability in the cancer’s survival machinery. Whether it ultimately proves to be a durable advance or a bridge to something better will depend on data that are still being gathered. For patients who have run out of standard options, that data cannot come soon enough.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
